Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advertisement
Zachary BessetteAdvanced Renal Cell Carcinoma | September 20, 2023
The FDA has accepted for priority review the sNDA for belzutifan in patients who were previously treated for advanced RCC.
Read More
Emily MenendezAdvanced Renal Cell Carcinoma | September 8, 2023
Improved PFS was associated with negative surgical margins and no 30-day surgical complications, plus pathologic downstaging.
Hans Hammers, MD, PhDRenal Cell Carcinoma | September 8, 2023
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
Zachary BessetteAdvanced Renal Cell Carcinoma | August 22, 2023
Belzutifan improves PFS in adult patients with advanced RCC who have progressed on previous PD-1/PD-L1 or VEGF-TKI therapies.
Emily MenendezAdvanced Renal Cell Carcinoma | August 11, 2023
Researchers investigated the impact of duration of exposure to antiangiogenics on immunotherapy outcomes in metastatic ccRCC.
Emily MenendezAdvanced Renal Cell Carcinoma | July 28, 2023
Researchers from the Mayo Clinic assessed the efficacy of ICI combination therapy as a first-line mRCC treatment.
Jérémie Calais, MD, MScSNMMI 2023 | July 25, 2023
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
Emily MenendezAdvanced Renal Cell Carcinoma | July 19, 2023
Researchers summarized the survival outcomes of patients with mRCC treated with CN after IO-based perioperative treatments.
Emily MenendezAdvanced Renal Cell Carcinoma | July 19, 2023
Research presented at KCRS23 characterized patients with an OR in the lenvatinib plus pembrolizumab arm of the CLEAR study.
Emily MenendezAdvanced Renal Cell Carcinoma | July 19, 2023
At KCRS23, researchers presented their data on the differences in clinical outcomes in patients with synchronous and metachro
Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023
Dr. Hutson provides an overview of different combination therapies used and investigated for first-line advanced RCC.
Emily MenendezAdvanced Renal Cell Carcinoma | July 10, 2023
The IMmotion150, IMmotion151, and JAVELIN Renal 101 trials were assessed for OS, PFS, and ORR of anti-PD-L1 combinations.
Laurence Albiges, MD, PhDASCO 2023 | July 6, 2023
Dr. Albiges details the KEYMAKER-U03B study, outcomes for patients in arm B5, and next lines of research for belzutifan.
Brian Rini, MD, FASCOASCO 2023 | June 5, 2023
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
Zachary BessetteASCO 2023 | June 5, 2023
Updated PFS data was presented for the first phase 3, randomized trial to test the benefit of ICI rechallenge in mRCC.
Zachary BessetteASCO 2023 | June 4, 2023
CBM588 may improve clinical outcomes for patients with mRCC when combined with the cabozantinib plus nivolumab.
Emily MenendezASCO 2023 | May 31, 2023
A study from ASCO 2023 surveyed patients to determine how they prioritize their treatment selection for mRCC.
Emily MenendezASCO 2023 | May 31, 2023
Researchers conducted an exploratory follow-up analysis of HRQoL in treament with nivolumab plus cabozantinib vs sunitinib.
Zachary BessetteASCO 2023 | May 26, 2023
A prospective study shows activity after treatment intensification with a triplet combination regimen in patients with RCCvh.
Advertisement
Advertisement
Advertisement